Skip to content

Study · Randomized controlled trial · n = 575 · 2001

3 results

Subset analysis of RTOG 85-31 and 86-10 indicates an advantage for long-term vs. short-term adjuvant hormones for patients with locally advanced nonmetastatic prostate cancer treated with radiation therapy.

Horwitz EM, Winter K, Hanks GE, Lawton CA, Russell AH, Machtay M

International journal of radiation oncology, biology, physics1 Mar 2001Cited by 60 (Europe PMC)

PMID11240235 (opens in a new tab)DOI10.1016/s0360-3016(00)01443-7 (opens in a new tab)PepBankPUB-11240235
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In RTOG 85-31 prostate cancer patients, long-term adjuvant goserelin improved biochemical disease-free survival versus radiation alone.

    In plain wordsIn prostate cancer patients in RTOG 85-31, long-term goserelin improved biochemical disease-free survival versus radiation alone.

    Peptide
    Goserelin
    Outcome
    IncreaseBiochemical disease-free survival in RTOG 85-31
    Study

    n = 575

    Comparator
    radiation alone
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated · indefinitelyAs given in this study (human).

    Source sentences

    Summary
    For all patients treated on 85-31, statistically significant improvements for bNED control, DMF, and CSF were observed between Group I and II.
    2 context sentences
    Summary · context
    Five hundred seventy-five patients with T3N0M0 disease were included from RTOG 85-31 and 418 patients with T2b-T4N0M0 disease from RTOG 86-10.
    Summary · context
    Patients randomized to receive long-term hormones (LTH) on 85-31 received goserelin starting the last week of RT and continued indefinitely.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In RTOG 85-31 prostate cancer patients, long-term adjuvant goserelin reduced distant metastases failure versus radiation alone.

    In plain wordsIn prostate cancer patients in RTOG 85-31, long-term goserelin reduced distant metastases failure versus radiation alone.

    Peptide
    Goserelin
    Outcome
    DecreaseDistant metastases failure in RTOG 85-31
    Study

    n = 575

    Comparator
    radiation alone
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated · indefinitelyAs given in this study (human).

    Source sentences

    Summary
    For all patients treated on 85-31, statistically significant improvements for bNED control, DMF, and CSF were observed between Group I and II.
    2 context sentences
    Summary · context
    Five hundred seventy-five patients with T3N0M0 disease were included from RTOG 85-31 and 418 patients with T2b-T4N0M0 disease from RTOG 86-10.
    Summary · context
    Patients randomized to receive long-term hormones (LTH) on 85-31 received goserelin starting the last week of RT and continued indefinitely.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In RTOG 85-31 prostate cancer patients, long-term adjuvant goserelin reduced cause-specific failure versus radiation alone.

    In plain wordsIn prostate cancer patients in RTOG 85-31, long-term goserelin reduced cause-specific failure versus radiation alone.

    Peptide
    Goserelin
    Outcome
    DecreaseCause-specific failure in RTOG 85-31
    Study

    n = 575

    Comparator
    radiation alone
    Outcome group
    Mortality · Cancer
    Studied dose
    Dose not stated · indefinitelyAs given in this study (human).

    Source sentences

    Summary
    For all patients treated on 85-31, statistically significant improvements for bNED control, DMF, and CSF were observed between Group I and II.
    2 context sentences
    Summary · context
    Five hundred seventy-five patients with T3N0M0 disease were included from RTOG 85-31 and 418 patients with T2b-T4N0M0 disease from RTOG 86-10.
    Summary · context
    Patients randomized to receive long-term hormones (LTH) on 85-31 received goserelin starting the last week of RT and continued indefinitely.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.